argenex (NASDAQ:ARGX – Get Free Report) had its target price raised by analysts at Royal Bank Of Canada from $890.00 to $945.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Royal Bank Of Canada’s target price suggests a potential upside of 2.07% from the company’s previous close.
ARGX has been the subject of a number of other research reports. Morgan Stanley upped their price objective on argenex from $1,170.00 to $1,180.00 and gave the company an “overweight” rating in a report on Wednesday, June 24th. Weiss Ratings reiterated a “hold (c)” rating on shares of argenex in a research report on Monday, April 20th. Oppenheimer reduced their price target on shares of argenex from $1,060.00 to $1,014.00 and set an “outperform” rating on the stock in a research report on Thursday, April 2nd. Deutsche Bank Aktiengesellschaft raised argenex from a “hold” rating to a “buy” rating in a research note on Tuesday, March 10th. Finally, Guggenheim raised their price target on argenex from $1,120.00 to $1,135.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, argenex presently has an average rating of “Moderate Buy” and an average price target of $1,037.61.
Get Our Latest Stock Analysis on ARGX
argenex Stock Performance
argenex (NASDAQ:ARGX – Get Free Report) last issued its earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share (EPS) for the quarter. The company had revenue of $1.31 billion for the quarter. argenex had a net margin of 31.31% and a return on equity of 44.37%. As a group, equities research analysts predict that argenex will post 26.27 earnings per share for the current year.
Hedge Funds Weigh In On argenex
Large investors have recently bought and sold shares of the company. Janus Henderson Group PLC lifted its position in shares of argenex by 3.4% in the first quarter. Janus Henderson Group PLC now owns 2,541,732 shares of the company’s stock worth $1,847,592,000 after purchasing an additional 83,568 shares in the last quarter. Capital World Investors lifted its position in argenex by 0.4% during the 3rd quarter. Capital World Investors now owns 1,959,504 shares of the company’s stock worth $1,445,113,000 after buying an additional 8,422 shares in the last quarter. M&T Bank Corp lifted its position in argenex by 20,977.7% during the 4th quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock worth $654,772,000 after buying an additional 774,916 shares in the last quarter. Wellington Management Group LLP boosted its stake in shares of argenex by 80.1% during the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock worth $538,408,000 after buying an additional 324,653 shares during the last quarter. Finally, Morgan Stanley grew its holdings in shares of argenex by 19.2% in the 4th quarter. Morgan Stanley now owns 518,852 shares of the company’s stock valued at $436,331,000 after acquiring an additional 83,746 shares in the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.
argenex Company Profile
argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.
The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.
Further Reading
- Five stocks we like better than argenex
- AI Insider Activity: Are Sales Across 3 Key Stocks Noteworthy or Just Noise?
- 3 Quiet AI Revenue Accelerators With Sales Growth Outpacing Peers
- Top 135 Best Locally Owned BBQ Supply Stores in the U.S., According to Survey [2026]
- Silicon Starvation: Amazon Feasts on Legacy GPUs
Receive News & Ratings for argenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenex and related companies with MarketBeat.com's FREE daily email newsletter.
